A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
Phase 1
52
about 2.8 years
18+
6 sites in CA, CO, IL +2
What this study is about
Researchers are testing if treatment with bulumtatug fuvedotin is effective in triple-negative breast cancer patients who have previously received treatment with an antibody-drug conjugates. The trial will last for 1024 days and involve approximately 52 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take bulumtatug fuvedotin
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Objective Response Rate
Secondary: Clinical benefit rate, Disease control rate, Duration of response, Half-life (t1/2), Immunogenicity, Incidence, rate and severity of treatment-emergent adverse events., Maximum Concentration (Cmax), Overall survival
Oncology